Drugs / DTG/ABC/3TC
DTG/ABC/3TC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02893488 | Sep → Nov 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTG/ABC/3TC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02893488 ↗ |
| Known as | abacavir/dolutegravir/lamivudine | “The fixed-dose combination (FDC) tablet formulation of abacavir/dolutegravir/lamivudine is indicated for the treatment of HIV-1 infection in adults and pediatric patients...” PMID 30239425 ↗ Dec 2018 |
| Known as | TRIUMEQ | “Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately.” NCT02893488 ↗ |
| Route | Oral | “Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately.” NCT02893488 ↗ |